Effects of histamine dihydrochloride on immunological biomarkers and minimal residual disease in patients with acute myeloid leukaemia in first remission.

Trial Profile

Effects of histamine dihydrochloride on immunological biomarkers and minimal residual disease in patients with acute myeloid leukaemia in first remission.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 19 Apr 2016

At a glance

  • Drugs Histamine dihydrochloride (Primary) ; Interleukin-2
  • Indications Acute myeloid leukaemia
  • Focus Biomarker; Therapeutic Use
  • Acronyms RE:MISSION
  • Sponsors Immune Pharmaceuticals Inc
  • Most Recent Events

    • 19 Apr 2016 Biomarker data presented at the American Association for Cancer Research (AACR) Annual Meeting 2016, according to an Immune Pharmaceuticals Inc media release.
    • 12 Jan 2016 Results of this study in a biomarker-defined sub-population are expected in 2016, as per Immune Pharmaceuticals media release.
    • 25 Feb 2011 Results from this trial will be used to refine the EU labeling for Histamine-dihydrochloride [Ceplene].
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top